<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The discovery of pharmacogenomic markers in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) could be setting-specific </plain></SENT>
<SENT sid="1" pm="."><plain>FOLFOX4 is employed in the adjuvant and metastatic setting in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>This prospective study is aimed to validate in the adjuvant setting the pharmacogenomic markers of toxicity reported in the metastatic setting (that is, GSTP1-rs947894, and -rs1138272; GSTM1-null genotype; AGXT-rs4426527, -rs34116584 and del-74 bp), and to discover additional markers </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients (n=144) treated with adjuvant FOLFOX4 were genotyped for 57 polymorphisms in 29 genes </plain></SENT>
<SENT sid="4" pm="."><plain>Grade 2 neurotoxicity was associated (false discovery rate-adjusted q-value &lt;0.1) with single-nucleotide polymorphisms in ABCC1 (rs2074087: odds ratio=0.43(0.22-0.86)), and ABCC2 (rs3740066: 2.99(1.16-7.70); rs1885301: 3.06(1.35-6.92); rs4148396: 4.69(1.60-13.74); rs717620: 14.39(1.63-127.02)) </plain></SENT>
<SENT sid="5" pm="."><plain>hMSH6-rs3136228 was associated with grade 3-4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (3.23(1.38-7.57), q-value=0.0937) </plain></SENT>
<SENT sid="6" pm="."><plain>XRCC3-rs1799794 was associated with grade 3-4 non-hematological toxicity (8.90(2.48-31.97), q-value=0.0150) </plain></SENT>
<SENT sid="7" pm="."><plain>The markers previously identified in metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were not validated </plain></SENT>
<SENT sid="8" pm="."><plain>We have identified new markers of toxicity in genes of transport and DNA repair </plain></SENT>
<SENT sid="9" pm="."><plain>If validated in other studies, they could help to identify patients at risk of toxicity.The Pharmacogenomics Journal advance online publication, 7 August 2012; doi:10.1038/tpj.2012.31 </plain></SENT>
</text></document>